Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 98

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 98
---
otech Index, respectively. Historical stock performance is not necessarily indicative of future stock performance. |

| (5) | We determinednet product revenueto be the most important financial performance measure used to link company performance to Compensation Actually Paid to our PEOs andNon-PEONEOs in 2024. This performance measure may not have been the most important financial performance measure for years 2021 and 2020 and we may determine a different financial performance measure to be the most important financial performance measure in future years. Assumptions used in revenue recognition are described in Note 2, Summary of Significant Accounting Policies, to our Consolidated Financial Statements in our Annual Report on Form10-Kfor the year ended December 31, 2024, filed with the SEC on February 13, 2025. |

74

Relationship Between PEO and Non-PEONEO Compensation Actually Paid and Cumulative TSR The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEONEOs, and the company’s cumulative TSR over the five most recently completed fiscal years. The chart also compares the company’s cumulative TSR to that of the NASDAQ Biotech Index TSR over the same period. 75 Relationship Between PEO and Non-PEONEO Compensation Actually Paid and Net Income The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEONEOs, and our net income during the five most recently completed fiscal years. 76

Relationship Between PEO and Non-PEONEO Compensation Actually Paid and Net Product Revenue The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEONEOs, and our net product revenue during the five most recently completed fiscal years.

Tabular List of Most Important Financial and Non-FinancialPerformance Measures

The following table presents the financial and non-financial performance measures that the company considers to have been the most important in linking Compensation Actually Paid to our PEOs and other Non-PEO NEOs for 2024 to company performance. Of these measures, as noted above, we have identified net product revenue to be the most important financial performance measure used to link company performance to Compensation Actually Paid to our PEOs and Non-PEO NEOs in 2024.

| Net Product Revenue 
 Clinical Milestones 
 Research Milestones |

# # # 77
Sec